Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

56 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects.
Müller P, Flesch G, de Gasparo M, Gasparini M, Howald H. Müller P, et al. Eur J Clin Pharmacol. 1997;52(6):441-9. doi: 10.1007/s002280050317. Eur J Clin Pharmacol. 1997. PMID: 9342579 Clinical Trial.
Overview of the clinical pharmacokinetics of oxcarbazepine.
Flesch G. Flesch G. Clin Drug Investig. 2004;24(4):185-203. doi: 10.2165/00044011-200424040-00001. Clin Drug Investig. 2004. PMID: 17516704
In vitro, MHD is only a weak inducer of uridine diphospate (UDP)-glucuronyltransferase (UDPGT) and therefore is unlikely to have an effect on drugs that are mainly eliminated by conjugation through the UDPGT enzymes (e.g. valproic acid and lamotrigine). ...
In vitro, MHD is only a weak inducer of uridine diphospate (UDP)-glucuronyltransferase (UDPGT) and therefore is unlikely to have an effect o …
Pharmacokinetic interactions among imatinib, bosentan and sildenafil, and their clinical implications in severe pulmonary arterial hypertension.
Renard D, Bouillon T, Zhou P, Flesch G, Quinn D. Renard D, et al. Among authors: flesch g. Br J Clin Pharmacol. 2015 Jul;80(1):75-85. doi: 10.1111/bcp.12584. Epub 2015 Jun 1. Br J Clin Pharmacol. 2015. PMID: 25581063 Free PMC article. Clinical Trial.
Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine.
Flesch G, Czendlik C, Renard D, Lloyd P. Flesch G, et al. Drug Metab Dispos. 2011 Jun;39(6):1103-10. doi: 10.1124/dmd.109.030593. Epub 2011 Mar 9. Drug Metab Dispos. 2011. PMID: 21389120 Clinical Trial.
Comparison of plasma and saliva concentrations of the active monohydroxy metabolite of oxcarbazepine in patients at steady state.
Cardot JM, Degen P, Flesch G, Menge P, Dieterle W. Cardot JM, et al. Biopharm Drug Dispos. 1995 Oct;16(7):603-14. doi: 10.1002/bdd.2510160708. Biopharm Drug Dispos. 1995. PMID: 8785383 Clinical Trial.
Clinical pharmacology and pharmacokinetics of oxcarbazepine.
Lloyd P, Flesch G, Dieterle W. Lloyd P, et al. Epilepsia. 1994;35 Suppl 3:S10-3. doi: 10.1111/j.1528-1157.1994.tb05938.x. Epilepsia. 1994. PMID: 8156973 Review.
Furthermore, OCBZ itself does not appear to induce the cytochrome P-450 family in general, although it does induce the P-450 IIIA subfamily, which is responsible for the metabolism of estrogens and the dihydropyridine calcium-channel blockers (e.g., nifedipine, felodipine) …
Furthermore, OCBZ itself does not appear to induce the cytochrome P-450 family in general, although it does induce the P-450 IIIA subfamily, …
Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose.
Waldmeier F, Flesch G, Müller P, Winkler T, Kriemler HP, Bühlmayer P, De Gasparo M. Waldmeier F, et al. Xenobiotica. 1997 Jan;27(1):59-71. doi: 10.1080/004982597240767. Xenobiotica. 1997. PMID: 9041679
The influence of food on the disposition of the antiepileptic oxcarbazepine and its major metabolites in healthy volunteers.
Degen PH, Flesch G, Cardot JM, Czendlik C, Dieterle W. Degen PH, et al. Biopharm Drug Dispos. 1994 Aug;15(6):519-26. doi: 10.1002/bdd.2510150609. Biopharm Drug Dispos. 1994. PMID: 7993989 Clinical Trial.
Assessment of the bioequivalence of two oxcarbazepine oral suspensions versus a film-coated tablet in healthy subjects.
Flesch G, Tudor D, Denouel J, Bonner J, Camisasca R. Flesch G, et al. Int J Clin Pharmacol Ther. 2003 Jul;41(7):299-308. doi: 10.5414/cpp41299. Int J Clin Pharmacol Ther. 2003. PMID: 12875346 Clinical Trial.
56 results
Jump to page
Feedback